RESPIRATORY SYNCYTIAL VIRUS AND CHILD PNEUMONIA WEBINAR
Listen to talks by:
- Dr. Ting Shi (University of Edinburgh): Global disease burden estimate of RSV in young children
- Dr. Marijke Proesmans (Katholieke Universiteit Leuven): RSV therapeutics
- Dr. Keith Klugman (Director, Pneumonia, Bill&Melinda Gates Foundation): RSV immunization and future directions
- Dr. Louis Bont (Chairman ReSViNET Foundation): RSV clinical presentation and disease severity
Visual
Use the link below to access the SlideShare presentation for the talks:
https://www.slideshare.net/secret/H0MzMgF2seNUX7
NOTE: Please download this slide deck from the SlideShare platform to view.
Audio
Using free conference calling, you can use the dial-in numbers provided below OR call in via your web browser. Cell phone carrier rates may apply standard charges using the provided dial-in numbers. Check with your cell phone carrier to see if long-distance calling rates will apply. Instructions for calling in via the web browser option are also listed below.
To call into the webinar via your telephone:
Conference access code:
648476
Dial-in number (U.S. and Canada):
(605) 475-4053
International dial-in numbers:
United Kingdom: +44 330 998 1320
Australia: +61 2 6194 9930
India: +91 172 519 9261
If you do not see your country’s dial-in number listed above, please see HERE.
To call into the webinar using a web browser:
Enter the following link into a new browser page: join.freeconferencecall.com/couasnonm0
Select ‘Join online meeting.’ You will be prompted to enter your name and email and join the meeting. If prompted, follow the FCC installer download instructions.
Click the telephone icon on the top left (audio preferences).
Select the ‘Mic and speakers’ option to call from your computer and use your Wifi connection to be placed into the conference call.
Use the link below to access the SlideShare presentation for the talks:
https://www.slideshare.net/secret/H0MzMgF2seNUX7
NOTE: Please download this slide deck from the SlideShare platform to view.
Audio
Using free conference calling, you can use the dial-in numbers provided below OR call in via your web browser. Cell phone carrier rates may apply standard charges using the provided dial-in numbers. Check with your cell phone carrier to see if long-distance calling rates will apply. Instructions for calling in via the web browser option are also listed below.
To call into the webinar via your telephone:
Conference access code:
648476
Dial-in number (U.S. and Canada):
(605) 475-4053
International dial-in numbers:
United Kingdom: +44 330 998 1320
Australia: +61 2 6194 9930
India: +91 172 519 9261
If you do not see your country’s dial-in number listed above, please see HERE.
To call into the webinar using a web browser:
Enter the following link into a new browser page: join.freeconferencecall.com/couasnonm0
Select ‘Join online meeting.’ You will be prompted to enter your name and email and join the meeting. If prompted, follow the FCC installer download instructions.
Click the telephone icon on the top left (audio preferences).
Select the ‘Mic and speakers’ option to call from your computer and use your Wifi connection to be placed into the conference call.
|
Recent RESVINET PUBLICATIONsEXPERT CONSENSUS ON PALIVIZUMAB USE FOR RESPIRATORY SYNCYTIAL VIRUS IN DEVELOPED COUNTRIES Sánchez Luna M, Manzoni P, Paes B, Baraldi E, Cossey V, Kugelman A, Chawla R, Dotta A, Rodríguez Fernández R, Resch B, Carbonell-Estrany X. Abstract Respiratory syncytial virus (RSV) infection is a leading cause of hospitalisation in early childhood and palivizumab is the only licensed intervention for prevention. Palivizumab guidelines should reflect the latest evidence, in addition to costs-effectiveness and healthcare budgetary considerations. RSV experts from Europe, Canada and Israel undertook a systematic review of the evidence over the last 5 years and developed recommendations regarding prophylaxis in industrialised countries. ..read more |
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. |
ABOUT RESVINET FOUNDATION |
PAPER OF THE MONTHThe endangered future of Syngem, a novel bacterium-like particle based, needle-free, RSV vaccine
Ascough S, Vlachantoni I, Kalyan M, Haijema BJ, Wallin- Weber S, Dijkstra-Tiekstra M, Ahmed MS, Roosmalen M van, Grimaldi R, Zhang Q, Leenhouts K, Openshaw PJ and Chiu C. Despite numerous years of research we are still lacking a safe and effective RSV vaccine. This process is hindered by numerous problems: the lack of a correlate of protection being one of them.That this has major consequences for vaccine development, is illustrated by the study performed by Stephanie Ascough, Peter Openshaw and colleagues. In their paper they describe the results of a randomized controlled, phase 1 trial of a novel needle-free RSV vaccine: SynGEM. The vaccine is based on a stable pre-fusion F antigen of the virus, and uses a bacterium-like-particle (BLP) as an immune-enhancing carrier. The study confirms that the vaccine is safe and that it is capable of inducing a mild (about 2 to 3-fold), but prolonged, increase in RSV-specific antibodies. However, the study didn’t reach the endpoint threshold and for now, SynGEM is withheld from proceeding to next phase trials. This study illustrates, that the lack of a correlate of protection brings an uncertainty to the table, which could lead to the premature termination of a potentially effective RSV vaccine. The use of a human challenge model (HCM) in RSV vaccine development would offer the possibility to circumvent this insecurity. Furthermore it might accelerate RSV-vaccine development. Written by Sjanna Besteman |
ReSViNET Global partners
